ICO Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.01 25.00
Close 0.05 1 Month 0.00 0.00
Volume 90000 1 Year -0.02 -28.57
52 Week High 0.09
52 Week Low 0.03
ICO Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
BML 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
DDX 0.50 100.00%
WRP 0.02 100.00%
CWM 0.14 100.00%
BVQ 0.02 100.00%
BRU 0.04 100.00%
BRU 0.04 100.00%
BRU 0.04 100.00%
More..
CVE Canada Top Losers Stocks
ADE 0.00 -100.00%
PKC-H 0.02 -71.43%
CBE 0.01 -50.00%
CBE 0.01 -50.00%
CBE 0.01 -50.00%
CVR 0.02 -50.00%
CVR 0.02 -50.00%
CVR 0.02 -50.00%
XAG 0.02 -50.00%
FEM 0.02 -50.00%
More..

ICO Therapeutics Inc (CVE: ICO)

ICO Technical Analysis 3
As on 24th Jul 2017 ICO Share Price closed @ 0.05 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.05 & Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICO Target for July
1st Target up-side 0.07
2nd Target up-side 0.08
3rd Target up-side 0.09
1st Target down-side 0.03
2nd Target down-side 0.02
3rd Target down-side 0.01
ICO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.icotherapeutics.com
ICO Address
ICO
760-777 Hornby Street
Vancouver, BC V6Z 1S4
Canada
Phone: 604-602-9414
Fax: 604-602-9699
ICO Latest News
Interactive Technical Analysis Chart ICO Therapeutics Inc ( ICO CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ICO Therapeutics Inc
ICO Business Profile
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.